Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22,15:50-17:40
AI Reshaping the End-to-End Clinical R&D Session
Stay tuned
Meeting Planner & Moderator: Shanshan Zhao – CEO, Q2BI
15:50-15:55 Opening Address
Shanshan Zhao: CEO, Q2BI
15:55-16:10 Efficiency Leap in Clinical R&D: AI-Driven Next-Generation Growth Engine
Simon Lin: Vice President of Biometrics, Q2BI
16:10-16:25 Medical Research "Autopilot": AI Agents Accelerating Clinical Data Governance and Statistical Practice
Meishuo Ouyang: Vice President, XY Health
16:25-16:40 From General-Purpose to Vertical: How AI Agents Crack Real Pain Points in Clinical R&D
Weijie Deng: Senior Manager of Biometrics, Q2BI
16:40-16:55 Smart Money's Judgment: When Will the Clinical AI Sector Take Off?
Haiyong Mo: Executive Vice President, Guangdong China Science and Tech Innovation Venture Capital Management Co., Ltd.
16:55-17:40 Roundtable: Real-Time Clinical Trials — From FDA Vision to AI Implementation
Moderator: Shanshan Zhao (CEO, Q2BI)
Panelists:
Yaning Wang (Founder & CEO, Ruiningkang Pharma; Former Director at FDA)
Yehua Zhu (Vice President of Clinical Development, Elpiscience)
Will Ma (Founder & CEO, HopeAI)
Jian Lun (CEO, XY Health)
Simon Lin (Vice President of Biometrics, Q2BI)